[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555958":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":25,"responsibleParty":35,"collaborators":38,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":85,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":25},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sham Comparator（Normal oral cecum transit time）","SHAM_COMPARATOR","Normal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g\u002F time, 4 times\u002Fday) was discontinued after 14 days of treatment.",[13],"Drug: Rifaximin",{"label":15,"type":16,"description":17,"interventionNames":18},"Experimental（Abnormal oral cecum transit time）","EXPERIMENTAL","Abnormal oral cecum transit time +functional abdominal distention +small intestinal bacterial overgrowth.Rifaximin (0.2g\u002F time, 4 times\u002Fday) was discontinued after 14 days of treatment.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Rifaximin","Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Jing-Nan Li, MD,Ph.D","PRINCIPAL_INVESTIGATOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},"CONTACT","13601235229","Jing-NanLilijn2008@126.com",{"type":29,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Jing-Nan Li","Chief physician, Professor",[39,41,43,45,47,49,51,53,55,57,59],{"name":40,"class":6},"Navy General Hospital, Beijing",{"name":42,"class":6},"Air Force Military Medical University, China",{"name":44,"class":6},"Beijing Tongren Hospital",{"name":46,"class":6},"Beijing Friendship Hospital",{"name":48,"class":6},"Beijing Chao Yang Hospital",{"name":50,"class":6},"Beijing Tiantan Hospital",{"name":52,"class":6},"The Luhe Teaching Hospital of the Capital Medical University",{"name":54,"class":6},"China-Japan Friendship Hospital",{"name":56,"class":6},"Beijing Aerospace General Hospital",{"name":58,"class":6},"Beijing Jishuitan Hospital",{"name":60,"class":6},"Peking University Third Hospital","100555958","phase-1-study-of-clinical-features-and-efficacy-of-small-intestinal-bacterial-overgrowth-in-patients-with-abdominal-distension-100555958",false,"NCT06518850","Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension","A Multicentre Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Abdominal Distension Patients","Inclusion criteria:\n\nPart 1 Clinical characteristics of small intestinal bacterial overgrowth in patients with abdominal distension of different etiologies\n\n1. Age 18-60 years old and gender;\n2. The chief complaint is abdominal distension and\u002For abdominal distension, abdominal distension and\u002For abdominal distension more prominent than other symptoms.\n\nPart 2 Efficacy observation of functional abdominal distention combined with small intestine bacterial overgrowth\n\n1. Patients with functional abdominal distension and small intestinal bacterial overgrowth were selected in Part 1;\n2. No drug contraindications.\n\nExclusion criteria:\n\nPart 1 Clinical characteristics of small intestinal bacterial overgrowth in patients with abdominal distension of different etiologies\n\n1. Preparation for pregnancy, pregnancy, breastfeeding women, or overall poor compliance, or other conditions that the investigator believes need to be excluded;\n2. History of malignant tumors, history of abdominal surgeries;\n3. Food intolerance, confirmed or suspected lactose intolerance;\n4. Diagnosis of urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's disease, etc.), mental system (depression, etc.) and other diseases outside the digestive system;\n5. Antibiotics and microecological preparations should be used within two weeks. Use motility enhancers, secretagogues, antifoaming agents, spasmolytics, opioids, antidepressants and other medications within a week.\n\nPart 2 Efficacy observation of functional abdominal distention combined with small intestine bacterial overgrowth\n\n1. Antibiotics and microecological preparations should be used within two weeks;\n2. Use motility enhancers, secretagogues, antifoaming agents, spasmolytics, opioids, antidepressants and other medications within a week.","ALL","18 Years","60 Years",{"count":72,"type":73},30,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE1","PHASE2","Most studies of bloating have focused on functional factors, while data on organic abdominal distention are rare, and studies that combine small intestine bacterial overgrowth and\u002For oral cecum transit time abnormalities are more urgent to explore. On this basis, patients with functional abdominal distension complicated with small intestine bacterial overgrowth were divided according to whether there was abnormal oral cecum transit time, and given the same treatment plan. The relief effect of abdominal distension, small intestine bacterial overgrowth turning negative and oral cecum transit time recovery were observed, so as to further clarify the cause of abdominal distension patients.",[80],"Small Intestine Bacterial Overgrowth",[82,83,84],"small intestine bacterial overgrowth","oral cecum transit time","abdominal distention","NOT_YET_RECRUITING","2024-07-18",{"date":88,"type":89},"2024-07-24","ACTUAL",{"date":91,"type":73},"2024-08-01",{"date":93,"type":73},"2025-12-31",{"name":5,"class":6}]